Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00929110 · ClinicalTrials.gov registry record · Phase 3
1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,066
- Enrollment target
NCT00929110 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 1,066 participants.
The verdict
NCT00929110, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,066 participants
- Enrollment target
Study Summary
This study was designed to investigate the 1 year efficacy and safety of the 50 µg once daily (od) dose of glycopyrronium bromide (NVA237) in patients with moderate to severe chronic obstructive pulmonary disease.
Interventions
- DRUG Tiotropium
- DRUG Glycopyrronium bromide
- DRUG Placebo to glycopyrronium bromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,066 participants |
| Start Date | 2009-06 |
| Est. Completion | 2011-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00929110
The ClinicalTrials.gov registry entry for NCT00929110 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,066 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tiotropium is the first listed.
NCT00929110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00929110 about?
NCT00929110 is a clinical study titled "1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)". This study was designed to investigate the 1 year efficacy and safety of the 50 µg once daily (od) dose of glycopyrronium bromide (NVA237) in patients with moderate to severe chronic obstructive pulmonary disease.
What is the current status of trial NCT00929110?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,066 participants. The study started on 2009-06. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00929110?
The interventions under investigation include: Tiotropium (DRUG), Glycopyrronium bromide (DRUG), Placebo to glycopyrronium bromide (DRUG).
Who is sponsoring clinical trial NCT00929110?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.